(19)

(11)

EP 2 307 379 A2

(12)

(88) Date of publication A3: 14.05.2010 (43) Date of publication: 13.04.2011 Bulletin 2011/15 (21) Application number: 09769332.9 (22) Date of filing: 25.06.2009

(51) International Patent Classification (IPC):  C07D 213/81(2006.01) C07D 413/04(2006.01) C07D 417/14(2006.01) A61K 31/4439(2006.01) A61P 3/10(2006.01) C07D 401/04(2006.01) C07D 413/14(2006.01) C07D 401/14(2006.01) A61K 31/444(2006.01) A61P 9/12(2006.01) (86) International application number: PCT/EP2009/057998 (87) International publication number: WO 2009/156484 (30.12.2009 Gazette 2009/53)

(84) Designated Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR Designated Extension States: AL BA RS (30) Priority: 27.06.2008 US 76443 (71) Applicants: Novartis AG 4056 Basel (CH) Xenon Pharmaceuticals Inc. Burnaby, BC V5G 4W8 (CA)

(72) Inventors: DALES, Natalie Cambridge, Massachusetts 02139 (US) ZHANG, Zaihui Burnaby, British Columbia V5G 4W8 (CA) FU, Jianmin Burnaby, British Columbia V5G 4W8 (CA) HOU, Duanjie Burnaby, British Columbia V5G 4W8 (CA) SUN, Shaoyi Burnaby, British Columbia V5G 4W8 (CA) KODUMURU, Vishnumurthy Burnaby, British Columbia V5G 4W8 (CA) POKROVSKAIA, Natalia Burnaby, British Columbia V5G 4W8 (CA) (74) Representative: Campbell, Lachlan Clive et al Novartis Pharma AG Patent Department 4002 Basel 4002 Basel (CH)